Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from its novel human-in-mouse (HIM) tissue transgenic cancer model system, in which AVEO successfully created invasive human tumors that develop over time in mice from primary human breast tissue. This model enables scientists, for the first time, to generate and study in vivo, human tumor initiation, progression and treatment in a preclinical model. This groundbreaking model was presented today in a session entitled "Mouse Models of Cancer 6: Signaling Mechanisms in Initiation, Progression and Therapeutics" at the 100th American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, California.

"For decades, human cancer cell line-derived xenografts have been the in vivo models of choice for pre-clinical studies, and with a few notable exceptions, those xenograft models have not been predictive of human clinical efficacy," said Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals. "As a result, clinical development in oncology remains largely empirical, resulting in a greater than 90 percent failure rate and long development timelines with significant capital risk. We believe our HIM model represents the next generation in modeling that will ultimately revolutionize early clinical development."

Murray O. Robinson, PhD, senior vice president of Translational Research at AVEO, added, "One issue with cell line xenografts is that the cell culture conditions for establishing cancer cell lines impart strong selection pressures that are different from those experienced by cells in an in vivo environment. Our proprietary models as part of the Human Response Prediction(TM) Platform provide a defined genetic context as well as an accurate tissue context in which to validat
'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... quarter results and conference call with investors to July ... 2014.  The Company rescheduled the release date and conference ... services for Hideo Watanabe , President of STAAR ...
(Date:7/28/2014)... 2014 Reportbuyer.com has added a new market ... 2014-2018 https://www.reportbuyer.com/product/2225723/Global-Bone-Densitometers-Market-2014-2018.html ... a special type of X-ray test used to measure ... primarily to detect osteopenia or osteoporosis, diseases in which ... fractures is high. The purpose of bone densitometry is ...
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2
... - Amgen,(Nasdaq:AMGN) today presented the results from a ... safety of Aranesp(R) (darbepoetin alfa) for the,treatment of ... or radiotherapy ("the 103 study"). Aranesp is not,approved ... these patients. These,results were presented in an oral ...
... therapeutic approach for the treatment,of early and metastatic ... - AEterna,Zentaris Inc. , a global, pure play ... presented an,abstract outlining in vivo data for its ... at the American,Association for Cancer Research (AACR) Annual ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:7/29/2014)... Healthcare staffing agency Medical Solutions is ... Scholarship Competition winners:, ,     Alonso B., ...     Racheal D., Freshman, Cerritos College in Norwalk, CA ... in Houston, TX , Each year, ... the Nurses of Tomorrow Scholarship competition as a ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen ... will utilize the Global Data Synchronization Network™ (GDSN®) ... share product information with the U.S. Food and ... their global supply chain. Holger Clobes, Head of ... "B. Braun serves customers in 61 countries, among ...
(Date:7/29/2014)... Mach7 Technologies, an award-winning provider of ... of an enhanced version of its Physician & ... & Patient Portal enables direct communication and collaboration ... a comprehensive view of their care history, including ... care records and intelligently delivers access to records ...
(Date:7/29/2014)... 2014 The Affordable Care Act has ... all hospitals. Studies show that over 400 hospitals probably ... low cost tool that great hospitals use to survive ... 25%. , Their secret? Debriefing - the simple process ... end of an operational event. Debriefing is a standard ...
(Date:7/29/2014)... July 29, 2014 TMG Health, ... solutions for health plans in the Medicare Advantage, ... markets recently held its annual Client Forum at ... the conference theme, “Partners in Excellence: Navigating the ... and operations leaders from TMG Health’s Client base ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 2Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3
... DALLAS, Oct. 27 , Robert A. Douglas, ... (RJR) , RJR Focus: SHC Career Division national sales ... over 20 years of previous sales management experience and over ... with SHC he has been fundamental in the development and ...
... ... Campus Compact and First Lady Michelle Obama for its commitment to public service and civic ... North Brunswick, NJ ... recognized at a gala luncheon hosted by the Florida Campus Compact and First Lady Michelle ...
... Calif., Oct. 27 Hauling multiple weapons into hunting grounds or ... those sportsmen who like to mix and match rifles and handguns. ... damage or lose prized possessions while in the hunt for big ... the new GunCruzer 2N2 Universal GunPod Case and wheel it to ...
... phones as far as possible from body, research suggests , MONDAY, ... hip may reduce bone density in an area of the pelvis ... researchers used dual X-ray absorptiometry to measure bone density at the ... carried their cell phones on their belts. The men carried their ...
... Ontario, Oct. 26 CardioGenics Holdings Inc. (OTC Bulletin Board: ... ticker symbol change for the Company on the OTCBB will ... 27, 2009. The new ticker symbol for "CardioGenics Holdings ... addition to the name and ticker symbol change that is ...
... Oct. 26 A free 40-minute webinar, ... , is being sponsored by Compirion Healthcare Solutions, ... Wisconsin. The webinar is premiering Wednesday, November 18th at ... http://www.compirion.com/webinars/seminar_healthcare_reform.cfm . This important webinar will ...
Cached Medicine News:Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 2Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 3Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 4Health News:Ross University School of Medicine Recognized for Commitment to Public Service and Civic Leadership 2Health News:CaseCruzer -- New GunCruzer 2N2Universal GunPod Case Makes Rifles and Handguns Travel Companions 2Health News:Cell Phone May Reduce Bone Density in Hips 2Health News:Free Webinar for CEOs on Preparing Your Hospital for Healthcare Reform 2Health News:Free Webinar for CEOs on Preparing Your Hospital for Healthcare Reform 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: